LONDON--(BUSINESS WIRE)--Osmetech plc (LSE:OMH), the international molecular diagnostics company announces that it has now commenced clinical trials for an extended warfarin sensitivity test.
LONDON--(BUSINESS WIRE)--Osmetech plc (LSE:OMH), the international molecular diagnostics company announces that it has now commenced clinical trials for an extended warfarin sensitivity test.